Dual antiplatelets therapy is a cornerstone treatment in patients with coronary artery disease at risk for ischemic events. The potent and long dual antiplatelets therapy reduces risk of ischemic coronary events but is associated with an increased risk of bleeding complications and a consequent higher morbidity and mortality. Because of the huge amount of new scientific data on DAPT the European Society of Cardiology and the European Association of Cardio-Thoracic Surgery have recently updated the guidelines. This short review gives the 'state of the art' of this important therapy.